Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Salubris Pharma Invests $5 Million in Boston's GO Therapeutics

publication date: Sep 26, 2017

Shenzhen Salubris Pharma made a $5 million investment in GO Therapeutics, a Cambridge, MA pre-clinical company. GO says it uses glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against intractable targets. GO currently has four candidates in pre-clinical studies, each of which includes a bi-specific mechanism that targets T-cells. The companies plan to have Salubris bring GO's drugs to China. The $5 million investment is the first funding that GO has announced. More details....

Stock Symbol: (SHZ: 2294)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.